Hims & Hers Trades 10% Above BofA's Raised $25 Target as Novo Nordisk Launches Direct Wegovy Sales

NEW YORK, April 16 —

BofA Securities lifted its price target on Hims & Hers Health, Inc. (NYSE: HIMS) to $25 from $21 while maintaining a Neutral rating, according to the firm's latest note, even as the shares trade near $27.50 on a rally tied to reports that the U.S. Food and Drug Administration is reassessing restrictions on compounded peptide treatments. The target revision leaves HIMS roughly 10% above BofA's upgraded fair value and about 15% above the $24 Wall Street consensus target, a positioning that frames the current move as a headline-driven trade rather than a valuation reset.

Background

Hims & Hers shares have moved sharply higher over the past week on reporting that the FDA is reviewing rules governing compounded peptide therapies, a category that includes semaglutide preparations sold through telehealth platforms. MarketWatch reported that the stock jumped as the U.S. moved forward with a plan to reassess popular peptides, and subsequent coverage from TipRanks and Seeking Alpha attributed the extended rally to public comments from Health and Human Services Secretary Robert F. Kennedy Jr. signaling a looser stance on peptide restrictions.

The compounding question matters because HIMS built a fast-growing GLP-1 franchise on compounded semaglutide, priced well below branded Wegovy and Zepbound. When the FDA previously declared the semaglutide shortage resolved, compounded supply faced tighter limits. A review that reopens a regulatory path for compounded peptides would, in theory, restore a portion of that runway. The key qualifier is that a review is not a rule change, and no new guidance has been published by the FDA.

Against that backdrop, Novo Nordisk, the maker of Wegovy and Ozempic, announced its first direct-to-consumer Wegovy subscription in the same news cycle. The program places the branded GLP-1 incumbent on the distribution model that HIMS popularized for this category, replacing a portion of the pharmacy and telehealth middle layer with a Novo-owned channel. Hims & Hers has not issued a public response to the Novo launch, according to its investor relations page.

Analyst View

Sell-side positioning on HIMS is cautious relative to the tape. BofA Securities raised its target to $25 from $21 while keeping a Neutral rating, framing the increase as a recalibration of multiple assumptions rather than a thesis change. The updated figure still sits below the current share price. The Wall Street consensus price target of $24, per compiled analyst data on Yahoo Finance, implies a roughly 12.7% drawdown from the April 16 quote of $27.50.

Seeking Alpha contributor coverage on April 15 argued that EBITDA multiples on HIMS have compressed far enough to matter once the "GLP-1 drama" fades, a bull-case framing that depends on the compounding path staying open and on branded competition remaining indirect. The BofA note and the consensus target imply the sell-side is not yet underwriting that outcome at current share prices.

Earnings history is mixed. HIMS has beaten the quarterly EPS estimate in three of the past four reports, most recently posting $0.20 against a $0.12 consensus, a roughly 66% beat on that print, followed by a $0.17 result versus a $0.16 estimate. Two quarters back, the company missed by roughly 39%, reporting $0.06 against a $0.10 estimate. The pattern is consistent with a business still operating at a scale where marketing spend, gross margin mix, and category expansion can swing quarterly results meaningfully.

What the Data Shows

The underlying business is profitable and cash-generative. Trailing-twelve-month revenue of $2.3bn, a gross margin near 73.8%, and free cash flow of roughly $111mn establish HIMS as a real operating story rather than a pre-revenue concept, per the company's most recent public filings. At 19.4x forward earnings, the multiple sits in the range of consumer-oriented digital health names that are already past the durable-profitability test.

The issue is positioning, not quality. The April 16 quote of $27.50 is roughly 10% above the $25 BofA target published this week, and about 15% above the $24 Street consensus. For a Neutral-rated stock, the implied message from the latest analyst action is that fair value has moved up but not to where the tape has moved. Two separate developments now pull against the rally narrative.

The first is that the FDA action is, to date, a review rather than a rule. The stock reacted to the framing of a reassessment and to public commentary, not to a published guidance document or a final order. A review can conclude in multiple directions, and any widening of the compounding pathway would typically be subject to defined conditions.

The second is competitive. Novo Nordisk's direct-to-consumer Wegovy subscription replicates the distribution model that allowed HIMS to sell compounded GLP-1 treatments at a price advantage to branded therapy. If branded GLP-1 is available directly from the manufacturer on a subscription, the price spread that justified compounded alternatives narrows, and the moat shifts from price to service, brand, and adjacent prescribing. That is a harder case to underwrite at a premium to consensus than a pure price-arbitrage pitch.

Insider activity over the past 90 days, disclosed through Form 4 filings on SEC EDGAR, shows open-market sales by several named executives, including the Chief Operating Officer, Chief Financial Officer, and Chief Legal Officer. The sales may have been executed under pre-arranged 10b5-1 plans; Form 4 disclosures do not state motivation. The pattern is worth flagging alongside the current rally but does not by itself support a directional conclusion.

Risks

The bull case for owning HIMS above consensus rests on three propositions: that the FDA review concludes in a way that durably reopens compounded peptide supply, that branded competitors fail to take share on direct distribution, and that the broader consumer health platform compounds at rates that justify a premium multiple even without GLP-1 upside. Each is plausible. None is currently priced as uncertain in the current quote.

The bear case is more specific. Should the FDA review conclude without a meaningful widening of the compounding pathway, the narrative that drove the recent rally loses its support. Should Novo Nordisk's direct-to-consumer Wegovy offer gain traction, the addressable share of GLP-1 prescribing available to a telehealth compounder shrinks, regardless of the regulatory outcome. The combination of a stretched setup relative to Street targets and a named pharma competitor moving onto the same distribution channel is the kind of two-variable pressure that reprices a story stock quickly.

There is also a technical element. A stock that trades 15% above consensus and 10% above the most recently raised sell-side target does not need a thesis-breaking catalyst to revert. Ordinary sentiment normalization, index-driven selling, or a quieter regulatory update can be sufficient. The cash-flow base is real enough to absorb that kind of move, but it does not prevent it.

Outlook

Hims & Hers has a working business: $2.3bn in annual revenue, gross margins in the low seventies, and positive free cash flow. The question for the next two to three quarters is whether the regulatory and competitive variables settle in a way that justifies trading above a recently raised Neutral target. BofA's $25 mark and the $24 consensus suggest that the sell-side, on balance, is not willing to underwrite that outcome at today's price. Novo Nordisk's direct Wegovy subscription introduces a credible price-and-distribution challenge to the exact franchise that drove HIMS's last leg of growth, and it landed on the same news cycle as the peptide-review reporting that fueled the rally. Investors considering a position at current levels should separate the regulatory signal from the regulatory outcome, and should weight the Novo launch as the more durable variable of the two.

Run the free Hims & Hers Health, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.

Frequently Asked Questions

Why did Hims & Hers stock rally this week?

Reporting indicated the FDA will reassess restrictions on compounded peptides, a category that includes semaglutide-class GLP-1s. Health and Human Services Secretary Robert F. Kennedy Jr. publicly signaled a looser posture, and traders priced the review as incrementally positive for the HIMS weight-loss franchise. No formal rule change has been issued.

Where does HIMS trade relative to analyst targets?

At approximately $27.50, the stock sits roughly 15% above the $24 consensus price target and roughly 10% above BofA Securities' $25 target, which BofA raised from $21 this week while maintaining a Neutral rating.

Why is Novo Nordisk's direct Wegovy subscription relevant to HIMS?

Novo's new subscription sells branded Wegovy directly to patients through the manufacturer's own channel, with bundled telehealth access. That is the distribution model HIMS has used to deliver compounded GLP-1s at a lower price. A competing direct channel from the drug's maker narrows the price gap that anchors the HIMS pitch.

How have HIMS insiders been transacting recently?

Four named officers, including the COO, CFO, and Chief Legal Officer, have executed open-market sales in the past 30 days, per Form 4 filings on SEC EDGAR. COO Michael Chi's March 17 sale of 97,289 shares at $24.69 (approximately $2.40 million) is the largest. The filings do not disclose whether the sales were executed under Rule 10b5-1 plans.

What should investors watch next?

Three data points: any formal FDA action on peptide compounding rules (as opposed to a review announcement); Q1 revenue disclosure for the weight-loss category to gauge the impact of Novo's subscription launch; and whether insider selling continues or reverses in the weeks following the rally.